Asthika Goonewardene
Stock Analyst at Truist Securities
(2.09)
# 2,932
Out of 5,182 analysts
89
Total ratings
43.02%
Success rate
-8.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Downgrades: Hold | $134 → $120 | $114.80 | +4.53% | 6 | Feb 24, 2026 | |
| ZYME Zymeworks | Initiates: Buy | $40 | $26.00 | +53.85% | 1 | Dec 17, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $43 | $25.19 | +70.70% | 1 | Nov 25, 2025 | |
| GMAB Genmab | Reiterates: Buy | $49 → $48 | $27.65 | +73.60% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Reiterates: Buy | $127 → $145 | $138.80 | +4.47% | 3 | Nov 3, 2025 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $32 → $39 | $22.07 | +76.71% | 2 | Oct 7, 2025 | |
| JANX Janux Therapeutics | Initiates: Buy | $100 | $14.93 | +569.79% | 1 | Sep 10, 2025 | |
| RVMD Revolution Medicines | Initiates: Buy | $99 | $96.29 | +2.81% | 1 | Sep 5, 2025 | |
| EXEL Exelixis | Maintains: Buy | $56 → $49 | $43.99 | +11.39% | 11 | Jul 29, 2025 | |
| BNTX BioNTech SE | Reiterates: Buy | $151 → $155 | $89.62 | +72.95% | 3 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $88 → $71 | $17.99 | +294.66% | 2 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $10 | $2.62 | +281.68% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $10 | $1.36 | +635.29% | 4 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $15 | $3.32 | +351.81% | 6 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $19.22 | +82.10% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $150 | $25.71 | +483.43% | 6 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $2.32 | +72.41% | 5 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 | $1.86 | +921.51% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $432 | $6.43 | +6,618.51% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Hold | $120 | $8.45 | +1,320.12% | 1 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $100 → $60 | $1.39 | +4,216.55% | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $228 → $180 | $11.13 | +1,517.25% | 4 | Aug 23, 2022 |
Arcellx
Feb 24, 2026
Downgrades: Hold
Price Target: $134 → $120
Current: $114.80
Upside: +4.53%
Zymeworks
Dec 17, 2025
Initiates: Buy
Price Target: $40
Current: $26.00
Upside: +53.85%
ArriVent BioPharma
Nov 25, 2025
Initiates: Buy
Price Target: $43
Current: $25.19
Upside: +70.70%
Genmab
Nov 7, 2025
Reiterates: Buy
Price Target: $49 → $48
Current: $27.65
Upside: +73.60%
Gilead Sciences
Nov 3, 2025
Reiterates: Buy
Price Target: $127 → $145
Current: $138.80
Upside: +4.47%
Arcus Biosciences
Oct 7, 2025
Reiterates: Buy
Price Target: $32 → $39
Current: $22.07
Upside: +76.71%
Janux Therapeutics
Sep 10, 2025
Initiates: Buy
Price Target: $100
Current: $14.93
Upside: +569.79%
Revolution Medicines
Sep 5, 2025
Initiates: Buy
Price Target: $99
Current: $96.29
Upside: +2.81%
Exelixis
Jul 29, 2025
Maintains: Buy
Price Target: $56 → $49
Current: $43.99
Upside: +11.39%
BioNTech SE
Jun 3, 2025
Reiterates: Buy
Price Target: $151 → $155
Current: $89.62
Upside: +72.95%
May 14, 2025
Maintains: Buy
Price Target: $88 → $71
Current: $17.99
Upside: +294.66%
May 14, 2025
Maintains: Buy
Price Target: $14 → $10
Current: $2.62
Upside: +281.68%
Apr 1, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $1.36
Upside: +635.29%
Mar 3, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $3.32
Upside: +351.81%
Jan 8, 2025
Initiates: Buy
Price Target: $35
Current: $19.22
Upside: +82.10%
Aug 16, 2024
Maintains: Buy
Price Target: $180 → $150
Current: $25.71
Upside: +483.43%
May 21, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $2.32
Upside: +72.41%
May 16, 2024
Maintains: Buy
Price Target: $19
Current: $1.86
Upside: +921.51%
Sep 6, 2023
Reiterates: Buy
Price Target: $432
Current: $6.43
Upside: +6,618.51%
Apr 5, 2023
Reinstates: Hold
Price Target: $120
Current: $8.45
Upside: +1,320.12%
Aug 23, 2022
Maintains: Hold
Price Target: $100 → $60
Current: $1.39
Upside: +4,216.55%
Aug 23, 2022
Maintains: Buy
Price Target: $228 → $180
Current: $11.13
Upside: +1,517.25%